What is Trulicity (Dulaglutide), how does it work, how do I use it?
Jeffrey Berger, MD: Deciding Between GLP1 Agonists or SGLT2 Inhibitors
Dr. Gobind Rai Garg discusses the topic - Amantadine
Nanome: Collaborative Structure-Based Drug Design in Virtual Reality
Dr. Paik on the Potential Approval of Lorlatinib for Patients With ALK-Positive NSCLC
Semaglutide is a pharmaceutical drug developed by Danish company Novo Nordisk for the treatment of type 2 diabetes. It is marketed by the name Ozempic. As a glucagon-like peptide-1 receptor agonist, it lowers the blood sugar level by increasing the production of insulin. It was discovered in 2012, by a team of researchers at Novo Nordisk as a longer-acting alternative to liraglutide. Clinical trials were started in 2015, and phase 3 was completed in 2016.